摘要
Oroxylin A(OA)is a natural flavonoid primarily derived from the plants Oroxylum indicum and Scutellaria baicalensis.Currently,OA is obtainable through chemical synthesis and exhibits polypharmacological properties,including anti-cancer,anti-inflammatory,anti-microbial,and multi-organ protective effects.The first-in-class drug OA tablets are presently undergoing phase Ib/IIa clinical trials for hepatocellular carcinoma(HCC)treatment.Substantial evidence suggests that OA demonstrates therapeutic potential against various hepatic and gastrointestinal(GI)disorders,including HCC,hepatic fibrosis,fatty liver disease,hepatitis,liver injury,colitis,and colorectal cancer(CRC).OA exerts its therapeutic effects primarily by modulating several crucial signaling pathways,including those associated with apoptosis,oxidative stress,inflammation,glucolipid metabolism,and fibrosis activation.The oral pharmacokinetics of OA is characterized by phase II metabolism,hydrolysis,and enterohepatic recycling.This review provides a comprehensive overview of the critical stages involved in the development of OA tablets,presenting a holistic perspective on the progression of this first-in-class drug from preclinical to clinical phases.It encompasses the synthesis of active pharmaceutical ingredients,pharmacokinetics,pharmacological efficacy,toxicology,drug delivery,and recent advancements in clinical trials.Importantly,this review examines the potential mechanisms by which OA may influence the gut-liver axis,hypothesizing that these interactions may confer health benefits associated with OA that transcend the limitations posed by its poor bioavailability.
基金
supported by the National Natural Science Foundation of China(No.82174027)
the Social Development Project of Jiangsu Provincial Key Research and Development Program(No.BE2021782)
Qinglan Project of Jiangsu Province.
